EA200401298A1 - Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение - Google Patents

Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение

Info

Publication number
EA200401298A1
EA200401298A1 EA200401298A EA200401298A EA200401298A1 EA 200401298 A1 EA200401298 A1 EA 200401298A1 EA 200401298 A EA200401298 A EA 200401298A EA 200401298 A EA200401298 A EA 200401298A EA 200401298 A1 EA200401298 A1 EA 200401298A1
Authority
EA
Eurasian Patent Office
Prior art keywords
low dose
entecavir
pharmaceutical compositions
liquid
composition
Prior art date
Application number
EA200401298A
Other languages
English (en)
Other versions
EA008102B1 (ru
Inventor
Дивиакант Десаи
Данпин Ли
Original Assignee
Бристоль-Майерз Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристоль-Майерз Сквибб Компани filed Critical Бристоль-Майерз Сквибб Компани
Publication of EA200401298A1 publication Critical patent/EA200401298A1/ru
Publication of EA008102B1 publication Critical patent/EA008102B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предложены жидкие фармацевтические композиции, содержащие низкую дозу энтекавира. В одном воплощении настоящего изобретения жидкая композиция энтекавира представляет собой готовую к употреблению композицию, которая является как стабильной, так и приемлемой на вкус. Во втором воплощении настоящего изобретения жидкую композицию энтекавира готовят из порошкообразной композиции в момент употребления. Композиции с низкой дозой энтекавира могут также включать, по меньшей мере, один компонент, выбранный из подсластителя, консерванта, корригирующего агента, буферного агента или их комбинаций. В состав жидких композиций энтекавира можно также вводить другие фармацевтически активными агенты.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401298A 2002-04-08 2003-04-03 Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение EA008102B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37067402P 2002-04-08 2002-04-08
PCT/US2003/010371 WO2003086367A1 (en) 2002-04-08 2003-04-03 Low dose liquid entecavir formulations and use

Publications (2)

Publication Number Publication Date
EA200401298A1 true EA200401298A1 (ru) 2005-02-24
EA008102B1 EA008102B1 (ru) 2007-04-27

Family

ID=29250568

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401298A EA008102B1 (ru) 2002-04-08 2003-04-03 Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение

Country Status (22)

Country Link
US (1) US20030190334A1 (ru)
EP (1) EP1492510A4 (ru)
JP (1) JP2005528389A (ru)
KR (1) KR20040099403A (ru)
CN (1) CN1319517C (ru)
AR (1) AR039388A1 (ru)
AU (1) AU2003226259A1 (ru)
BR (1) BR0309057A (ru)
CA (1) CA2481092A1 (ru)
EA (1) EA008102B1 (ru)
EC (1) ECSP045349A (ru)
HR (1) HRP20040893A2 (ru)
MX (1) MXPA04009735A (ru)
MY (1) MY131488A (ru)
NO (1) NO20044451L (ru)
NZ (1) NZ535535A (ru)
PE (1) PE20040324A1 (ru)
PL (1) PL372322A1 (ru)
RS (1) RS88404A (ru)
TW (1) TWI275392B (ru)
WO (1) WO2003086367A1 (ru)
ZA (1) ZA200407672B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN1732944B (zh) * 2005-09-02 2013-05-08 海南中和药业有限公司 恩替卡韦分散片及其制备方法
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
CN101869569A (zh) * 2009-04-21 2010-10-27 李迪 即用型恩替卡韦组合物
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CN102908312B (zh) * 2011-11-10 2014-06-04 陈小花 抗乙肝病毒液体组合物
US8517850B1 (en) * 2012-12-11 2013-08-27 Cobra Golf Incorporated Golf club grip with device housing
KR101462018B1 (ko) * 2013-04-01 2014-11-19 썬시스템즈(주) 엔테카비르 함유 구강 붕해형 필름제제
CN103301071A (zh) * 2013-06-03 2013-09-18 北京阜康仁生物制药科技有限公司 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法
JP2016527308A (ja) * 2013-08-06 2016-09-08 ドン クック ファーマシューティカル カンパニー リミテッド エンテカビル微小球及びこれを含む非経口投与用医薬組成物
CN106573003B (zh) * 2014-06-20 2022-04-01 西梯茜生命工学股份有限公司 含有恩替卡韦作为活性成分的药物制剂及其制备方法
CN104083374A (zh) * 2014-07-18 2014-10-08 石家庄创建医药科技有限公司 一种恩替卡韦口服液组合物
CN109984996B (zh) * 2018-01-02 2022-01-18 扬子江药业集团有限公司 恩替卡韦口服溶液及其制备方法
CN108434096A (zh) * 2018-06-20 2018-08-24 广州大光制药有限公司 一种恩替卡韦口服溶液及其制备方法
WO2020004652A1 (ja) * 2018-06-29 2020-01-02 学校法人同志社 エムリカサンを含む製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
CA2359110A1 (en) * 1999-01-12 2000-07-20 Ronald James Boon Combination of hepatitis b vaccine with antiviral agents
IL150447A0 (en) * 2000-02-29 2002-12-01 Bristol Myers Squibb Co Pharmaceutical compositions containing entecavir
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
MY131488A (en) 2007-08-30
CA2481092A1 (en) 2003-10-23
CN1658844A (zh) 2005-08-24
JP2005528389A (ja) 2005-09-22
NO20044451L (no) 2004-11-04
HRP20040893A2 (en) 2005-02-28
BR0309057A (pt) 2005-02-01
NZ535535A (en) 2006-09-29
MXPA04009735A (es) 2005-01-11
RS88404A (en) 2006-12-15
WO2003086367A1 (en) 2003-10-23
ECSP045349A (es) 2005-01-03
AU2003226259A1 (en) 2003-10-27
PE20040324A1 (es) 2004-05-29
EP1492510A1 (en) 2005-01-05
EA008102B1 (ru) 2007-04-27
KR20040099403A (ko) 2004-11-26
PL372322A1 (en) 2005-07-11
TWI275392B (en) 2007-03-11
ZA200407672B (en) 2005-10-12
US20030190334A1 (en) 2003-10-09
EP1492510A4 (en) 2006-01-11
CN1319517C (zh) 2007-06-06
AR039388A1 (es) 2005-02-16
TW200306840A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
EA200401298A1 (ru) Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
EA200301275A1 (ru) Капсулы для ингаляции
HUP0204136A2 (hu) Eljárások az interleukin-2 tüdőbe juttatására
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
ATE464062T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
RU2005109554A (ru) Раствор для применения в области ногтей и околоногтевого пространства
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
DE69805983D1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
BR0111678A (pt) Composições medicinais contendo derivados de propenona
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
BRPI0418115A (pt) formulação lìquida estável de hormÈnio de crescimento
DK1414467T3 (da) Topisk behandling af mastalgi
EA200100956A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
MXPA04004907A (es) Composiciones de acetaminofen.
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
NZ521533A (en) Veterinary compositions for the treatment of parasitic diseases containing rafoxanide
PT1200088E (pt) Composicao contendo paracetamol e drotaverina
DK1100463T3 (da) Injicerbare formuleringer indeholdende ramoplanin
WO2005035500A3 (en) Therapeutic agents useful for treating pain
TH63200A (th) สูตรผสมเอนทีคาเวอร์ชนิดของเหลวที่มีขนาดการใช้ยาต่ำ และการใช้
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU